Corcept Therapeutics Faces Shareholder Investigation After FDA Warnings

Corcept Therapeutics is under investigation by Hagens Berman Sobol Shapiro LLP for allegedly misleading investors about its drug relacorilant, a proposed treatment for hypercortisolism. The United States===Food and Drug Administration issued a complete response letter (CRL) for relacorilant, citing a lack of sufficient evidence of effectiveness and liver safety concerns. A Thomson Reuters===Reuters report on January 30, 2026, revealed that the United States===Food and Drug Administration had warned Corcept Therapeutics on multiple occasions not to submit its drug application, contradicting the company's prior assurances to investors about the drug's progress toward approval. This news caused Corcept Therapeutics' shares to tumble, resulting in a $3.2 billion loss in market capitalization since December 2025. The investigation is examining whether Corcept Therapeutics misled investors about the drug's efficacy, safety, and its communications with regulators, as well as potentially overstating its hypercortisolism business prospects.